A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine

FEMS Immunology and Medical Microbiology

Volumn 61, Issue 1, 2011, Pages 54-62

  Jazani, Nima Hosseini ^a   Sohrabpour, Mohammad ^b   Mazloomi, Ebrahim ^b   Shahabi, Shahram ^a,c  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alum; Naloxone; Novel adjuvant; Salmonella typhimurium

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; NALOXONE; PHOSPHATE BUFFERED SALINE; SALMONELLA TYPHIMURIUM VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL LOAD; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LIVER; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SPLEEN; SURVIVAL RATE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; CELL PROLIFERATION; CYTOKINES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LIVER; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; NALOXONE; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; SPLEEN; SURVIVAL ANALYSIS; VACCINES, INACTIVATED;

EID: 78651080102     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00747.x     Document Type: Article

References (34)

1. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV & Bayry J (2009) Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30: 287-295.
2. Bansal A, Paliwal PK, Sagi SS & Sairam M (2010) Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection. Mol Cell Biochem 337: 213-221.
3. Berman AS, Chancellor-Freeland C, Zhu G & Black PH (1996) Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 3: 141-149.
4. Bileviciute-Ljungar I & Spetea M (2001) Contralateral but not systemic administration of the kappa-opioid agonist U-50, 488 H induces anti-nociception in acute hindpaw inflammation in rats. Brit J Pharmacol 132: 252-258.
5. Burris S, Norland J & Edlin BR (2001) Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy 12: 237-248.
6. Carpenter GW & Carr DJ (1995) Pretreatment with beta-funaltrexamine blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology 29: 129-140.
7. Casadevall A (2003) Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect Immun 71: 4225-4228.
8. Casadevall A & Pirofski LA (2006) A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 91: 1-44.
9. De Gregorio E, Tritto E & Rappuoli R (2008) Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38: 2068-2071.
10. Friedman H, Newton C & Klein TW (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 16: 209-219.
11. Guo CJ, Douglas SD, Gao Z et al. (2004) Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 48: 259-266.
12. Gupta RK & Siber GR (1995) Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13: 1263-1276.
13. Harandi AM, Medaglini D & Shattock RJ (2010) Vaccine adjuvants: a priority for vaccine research. Vaccine 28: 2363-2366.
14. Hem SL & White JL (1995) Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 6: 249-276.
15. Jamali A, Mahdavi M, Shahabi S et al. (2007) Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathogenesis 43: 217-223.
16. Jamali A, Mahdavi M, Hassan ZM et al. (2009) A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol 21: 217-225.
17. Jazani NH, Worobec E, Shahabi S & Nejad GB (2005) Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model. Can J Microbiol 51: 319-324.
18. Jazani NH, Karimzad M, Mazloomi E et al. (2010) Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect 12: 382-388.
19. Lindblad EB (2004) Aluminium compounds for use in vaccines. Immunol Cell Biol 82: 497-505.
20. Marriott I & Bost KL (2000) IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol 165: 182-191.
21. Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE & Larregina AT (2007) In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. J Immunol 178: 7006-7017.
22. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW & Marrack P (2009) Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183: 4403-4414.
23. Mittrucker HW & Kaufmann SH (2000) Immune response to infection with Salmonella typhimurium in mice. J Leukocyte Biol 67: 457-463.
24. Molitor TW, Morilla A, Risdahl JM, Murtaugh MP, Chao CC & Peterson PK (1992) Chronic morphine administration impairs cell-mediated immune responses in swine. J Pharmacol Exp Ther 260: 581-586.
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
26. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE & Bramwell VW (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364: 272-280.
27. Peterson AM & Miller P (2006) Principles of Pharmacology in Pain Management. Pharmacotherapeutics for Advanced Practice: A Practical Approach (Poole V & Peterson AM, eds) pp. 66-77. Lippincott Williams & Wilkins, Philadelphia, PA.
28. Sacerdote P, di San Secondo VE, Sirchia G, Manfredi B & Panerai AE (1998) Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol 113: 465-469.
29. Sacerdote P, Gaspani L & Panerai AE (2000) The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann NY Acad Sci 917: 755-763.
30. Schijns VE (2003) Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 21: 829-831.
31. Su Z, Tam MF, Jankovic D & Stevenson MM (2003) Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect Immun 71: 5178-5187.
32. Tagliabue A & Rappuoli R (2008) Vaccine adjuvants: the dream becomes real. Hum Vaccin 4: 347-349.
33. Ulanova M, Tarkowski A, Hahn-Zoric M & Hanson LA (2001) The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69: 1151-1159.
34. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ & Narasimhan B (2009) Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 98: 1278-1316.